These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20635819)

  • 1. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 3. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacovigilance activities in Nepal.
    Palaian S; Mohamed Ibrahim MI; Mishra P; Alam K; Shankar PR; Thapa BB
    Drug Saf; 2010 Oct; 33(10):889-90. PubMed ID: 20812773
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacovigilance in clinical dentistry: overlooked or axiomatic?
    Carnelio S; Khan SA; Rodrigues G
    Gen Dent; 2011; 59(1):24-8; quiz 29-30, 80. PubMed ID: 21613036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting adverse effects: a practice to be encouraged.
    Prescrire Int; 2013 Mar; 22(136):83. PubMed ID: 23593701
    [No Abstract]   [Full Text] [Related]  

  • 7. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 8. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effect reporting: pharmaceutical companies can't be trusted.
    Prescrire Int; 2015 Nov; 24(165):256. PubMed ID: 26688890
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 12. Bad medicine. Monitoring programs target substandard drugs.
    Grens K
    Mod Healthc; 2013 May; 43(20):30-1. PubMed ID: 23947275
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug Safety Evaluation in China.
    Li L; Yin J
    Curr Allergy Asthma Rep; 2019 Jul; 19(9):39. PubMed ID: 31321555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages of adverse-effect reporting by patients.
    Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 18. Approval times and the safety of new pharmaceuticals.
    Rudholm N
    Eur J Health Econ; 2004 Dec; 5(4):345-50. PubMed ID: 15452739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance.
    Arlett P
    Drug Saf; 2019 May; 42(5):581-582. PubMed ID: 30637598
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.